Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 135

Results For "CEO"

2217 News Found

AGC to establish Life Science Company in 2023
News | November 10, 2022

AGC to establish Life Science Company in 2023

The Group will continue to make proactive investments of its management resources in the life science business


SeQuent Scientific to acquire 100% stake in Tineta Pharma
News | November 08, 2022

SeQuent Scientific to acquire 100% stake in Tineta Pharma

The acquisition is for an enterprise value of Rs. 218 crores


Advent International launches Cohance Lifesciences
News | November 02, 2022

Advent International launches Cohance Lifesciences

API platform to comprise of RA Chem Pharma, ZCL Chemicals and Avra Laboratories


Jubilant Ingrevia to invest Rs. 2,050 crore during FY 22-25
News | November 01, 2022

Jubilant Ingrevia to invest Rs. 2,050 crore during FY 22-25

Most of the new growth Capex investments are happening on the Specialty Chemicals and Nutrition side


NHA organises workshop to accelerate adoption of ABDM
Policy | November 01, 2022

NHA organises workshop to accelerate adoption of ABDM

The participants discussed the latest developments under ABDM that shall enable true interoperability in the health sector and how effective adoption of ABDM can pave the way towards Universal Health Coverage


Gland Pharma’s Q2 FY23 revenue stood at Rs. 1,044.4 Cr
News | October 27, 2022

Gland Pharma’s Q2 FY23 revenue stood at Rs. 1,044.4 Cr

Gland Pharma Q2 FY2023 consolidated net profit up at Rs. 241.24 Cr


ERES IV acquires a majority stake in Oncodesign Services
News | October 27, 2022

ERES IV acquires a majority stake in Oncodesign Services

Oncodesign Services (ODS ), with 600 clients in 33 countries and 227 employees worldwide, provides services from target identification to hit-to-lead and lead optimization through to IND filing.


Laurus Labs planning Rs. 2,000 Cr Capex
News | October 27, 2022

Laurus Labs planning Rs. 2,000 Cr Capex

On the Capex front, the company has invested Rs. 416 crore in the first half and it is broadly in line with our guidance for the two years around Rs. 2,000 crore across all the subsidiaries and divisions


CEPI and SK bioscience partner to advance mRNA vaccine technology
News | October 26, 2022

CEPI and SK bioscience partner to advance mRNA vaccine technology

CEPI will provide up to US$40 million in initial funding to support the development of mRNA-vaccine candidates against Lassa Fever virus


Novartis maintains growth momentum; Confirms FY’22 Group guidance
News | October 26, 2022

Novartis maintains growth momentum; Confirms FY’22 Group guidance

Pluvicto and Scemblix launches are progressing well and we are awaiting data in earlier lines of therapy.